FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002465493> ?p ?o ?g. }

• W2002465493 endingPage "262" @default.
• W2002465493 startingPage "257" @default.
• W2002465493 abstract "SUMMARY We investigated the ability of six different pooled human immunoglobulin (PHIG) preparations to inhibit the binding of anti-myeloperoxidase (MPO) antibodies to MPO. All six PHIG preparations inhibited the binding of anti-MPO antibodies from six sera to MPO in a concentration-dependent manner in the concentration range 0·016 10 mg/ml. There was considerable variation in the ability of each PHIG preparation to inhibit the binding of anti-MPO antibody in a given serum. Further differences were seen in the ability of a given PHIG to inhibit anti-MPO binding in different sera. F(ab′)2: fragments from two PHIG preparations also inhibited in a concentration-dependent manner anti-MPO binding to MPO in all six sera in the concentration range 0·002 2·65 mg/ml, with a maximum inhibition of 42%. Little inhibition was seen with F(ab′)2 of normal human IgG from individual donors (1·8–12·2% al the maximum concentration of 2 mg/ml). F(ab′)2 fragments from three anti-MPO containing sera and two affinity-purified anti-MPO antibodies were eluted by affinity chromatography from Sepharose-bound PHIG F(ab′)2 and showed anti-MPO antibody activity. We have shown that PHIG and F(ab′)2 fragments of PHIG inhibit anti-MPO binding to MPO, and further that F(ab′)2 fragments of PHIG bind to F(ab′)2 fragments of anti-MPO antibodies. These observations indicate binding between the variable regions of PHIG and the antigen binding site of anti-MPO antibodies, and are consistent with an anti-idiotypic reaction. The variability seen in the inhibitory effect of the different PHIG preparations in anti-MPO-positive sera implies differences in their anti-idiotype content, while the variability of the inhibitory effect of a particular PHIG preparation between different sera suggests heterogeneity in the idiotypic repertoire of anti-MPO antibodies. Such variations in the inhibitory effect of different PHIG preparations on antibody binding may be an important determinant of their therapeutic effect." @default.
• W2002465493 created "2016-06-24" @default.
• W2002465493 creator A5001675890 @default.
• W2002465493 creator A5008691009 @default.
• W2002465493 creator A5025389560 @default.
• W2002465493 creator A5027821315 @default.
• W2002465493 creator A5034530227 @default.
• W2002465493 creator A5054014010 @default.
• W2002465493 creator A5077940936 @default.
• W2002465493 date "1994-02-01" @default.
• W2002465493 modified "2023-09-27" @default.
• W2002465493 title "Anti-idiotypic activity against anti-myeloperoxidase antibodies in pooled human immunoglobulin" @default.
• W2002465493 cites W143501003 @default.
• W2002465493 cites W1495224833 @default.
• W2002465493 cites W1554331075 @default.
• W2002465493 cites W1632540242 @default.
• W2002465493 cites W190980055 @default.
• W2002465493 cites W1962264982 @default.
• W2002465493 cites W1970198433 @default.
• W2002465493 cites W1977987728 @default.
• W2002465493 cites W1979820418 @default.
• W2002465493 cites W1982489572 @default.
• W2002465493 cites W1996497569 @default.
• W2002465493 cites W1999635097 @default.
• W2002465493 cites W2003599894 @default.
• W2002465493 cites W2006235492 @default.
• W2002465493 cites W2008663482 @default.
• W2002465493 cites W2021030324 @default.
• W2002465493 cites W2036710073 @default.
• W2002465493 cites W2039582264 @default.
• W2002465493 cites W2045911949 @default.
• W2002465493 cites W2056977206 @default.
• W2002465493 cites W2060056853 @default.
• W2002465493 cites W2074832379 @default.
• W2002465493 cites W2086183699 @default.
• W2002465493 cites W2093173647 @default.
• W2002465493 cites W2107254198 @default.
• W2002465493 cites W2109238964 @default.
• W2002465493 cites W2127180052 @default.
• W2002465493 cites W2140903638 @default.
• W2002465493 cites W2156855152 @default.
• W2002465493 cites W2164905521 @default.
• W2002465493 cites W2287257499 @default.
• W2002465493 cites W2315160100 @default.
• W2002465493 cites W2341400992 @default.
• W2002465493 cites W237749206 @default.
• W2002465493 cites W33581678 @default.
• W2002465493 cites W4230153331 @default.
• W2002465493 doi "https://doi.org/10.1111/j.1365-2249.1994.tb06520.x" @default.
• W2002465493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1534939" @default.
• W2002465493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8306501" @default.
• W2002465493 hasPublicationYear "1994" @default.
• W2002465493 type Work @default.
• W2002465493 sameAs 2002465493 @default.
• W2002465493 citedByCount "22" @default.
• W2002465493 countsByYear W20024654932016 @default.
• W2002465493 countsByYear W20024654932017 @default.
• W2002465493 countsByYear W20024654932022 @default.
• W2002465493 countsByYear W20024654932023 @default.
• W2002465493 crossrefType "journal-article" @default.
• W2002465493 hasAuthorship W2002465493A5001675890 @default.
• W2002465493 hasAuthorship W2002465493A5008691009 @default.
• W2002465493 hasAuthorship W2002465493A5025389560 @default.
• W2002465493 hasAuthorship W2002465493A5027821315 @default.
• W2002465493 hasAuthorship W2002465493A5034530227 @default.
• W2002465493 hasAuthorship W2002465493A5054014010 @default.
• W2002465493 hasAuthorship W2002465493A5077940936 @default.
• W2002465493 hasBestOaLocation W20024654931 @default.
• W2002465493 hasConcept C153911025 @default.
• W2002465493 hasConcept C159654299 @default.
• W2002465493 hasConcept C179247698 @default.
• W2002465493 hasConcept C181199279 @default.
• W2002465493 hasConcept C185592680 @default.
• W2002465493 hasConcept C203014093 @default.
• W2002465493 hasConcept C203565725 @default.
• W2002465493 hasConcept C2776914184 @default.
• W2002465493 hasConcept C2779881004 @default.
• W2002465493 hasConcept C55493867 @default.
• W2002465493 hasConcept C86803240 @default.
• W2002465493 hasConceptScore W2002465493C153911025 @default.
• W2002465493 hasConceptScore W2002465493C159654299 @default.
• W2002465493 hasConceptScore W2002465493C179247698 @default.
• W2002465493 hasConceptScore W2002465493C181199279 @default.
• W2002465493 hasConceptScore W2002465493C185592680 @default.
• W2002465493 hasConceptScore W2002465493C203014093 @default.
• W2002465493 hasConceptScore W2002465493C203565725 @default.
• W2002465493 hasConceptScore W2002465493C2776914184 @default.
• W2002465493 hasConceptScore W2002465493C2779881004 @default.
• W2002465493 hasConceptScore W2002465493C55493867 @default.
• W2002465493 hasConceptScore W2002465493C86803240 @default.
• W2002465493 hasIssue "2" @default.
• W2002465493 hasLocation W20024654931 @default.
• W2002465493 hasLocation W20024654932 @default.
• W2002465493 hasLocation W20024654933 @default.
• W2002465493 hasOpenAccess W2002465493 @default.
• W2002465493 hasPrimaryLocation W20024654931 @default.
• W2002465493 hasRelatedWork W2002465493 @default.
• W2002465493 hasRelatedWork W2003154045 @default.

• next